Navigation Links
Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
Date:12/20/2013

PHILADELPHIA, Dec. 20, 2013 /PRNewswire/ -- Spark Therapeutics, a fully integrated, late-stage gene therapy company, announced today that President and Chief Executive Officer Jeffrey D. Marrazzo will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference. Marrazzo's presentation will highlight the company's progress in developing potentially curative, one-time gene therapies for the treatment of inherited blindness and hemophilia, and provide an overview of Spark's expertise and capabilities in the clinical development of adeno-associated virus (AAV) vectors.  The presentation will take place at 1:30 PM PT on Tuesday, January 14, 2014 in the Elizabethan C room at the Westin St. Francis in San Francisco, California.

About Spark Therapeutics                                                                                           

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. Our robust pipeline includes a Phase 3 program in RPE65 blindness and a Phase 1/2 program in hemophilia B, as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has an unparalleled track record of success in supporting clinical studies across diverse therapeutic areas and routes of administration. The company's expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark's team while at The Children's Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. To learn more visit www.sparktx.com.

For information contact:
Jess Rowlands
Feinstein Kean Healthcare
202-729-4089
jessica.rowlands@fkhealth.com


'/>"/>
SOURCE Spark Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Snoring Therapy Awarded The Prestigious Spark Award
2. Kalyspo Awarded Best of Ann Arbor SPARK Boot Camp
3. Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The U.S. cannabis market is growing ... use in 2016. According to a new report published by ... estimated $7.2 billion in 2016 and is projected to grow ... recreational sales are projected to jump from $2.6 billion in ... The market may grow faster as the estimate was based ...
(Date:2/23/2017)... , Feb. 22, 2017 This report analyzes analyzes the ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. ... Market data and analytics are derived from primary and secondary ...
(Date:2/23/2017)... Ill. , Feb. 23, 2017 Takeda ... subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition ... PLC and Ctrl Group Limited, announced a collaboration to ... an Apple Watch wearable to monitor and assess cognitive ... Depression (MDD) is the leading cause of disability ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... , ... Curemark, LLC announced today that the Blüm Study, a Phase 3 ... with Autism, is now enrolling at three new sites. These new sites are in ... , “There are currently no approved drugs that address the core symptoms of autism,” ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... treatment to the thousands of individuals who have recently fallen victim to America’s opioid ... in Orange County, California, where they are free from the shame, stigma, and ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
Breaking Medicine News(10 mins):